Skip to content
Screener

EPS (Diluted) at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$0.71+54.5%
Guardant Health logo
Guardant HealthGH
-$0.85-10.4%
Natera, Inc. logo
Natera, Inc.NTRA
-$0.47+36.5%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%
Myriad Genetics logo
Myriad GeneticsMYGN
-$0.36
Immunome logo
ImmunomeIMNM
-$0.48+7.7%

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$3.75B+111%
Enterprise value$3.88B+98.7%
P/S12.7×+4.0×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206546
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Loss from operations(19,206)(29,604)
Interest and other income, net2,0802,679
Interest expense(2,889)(2,905)
Net loss(20,015)(29,830)
Add: Net income attributable to noncontrolling interest(18)(22)
Net loss attributable to Adaptive Biotechnologies Corporation$(20,033)$(29,852)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted$(0.13)$(0.20)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted155,521,048149,195,028

Item 1. Financial Statements (Unaudited)

FAQ

What is Adaptive Biotechnologies's EPS (diluted)?
Adaptive Biotechnologies (ADPT) reported EPS (diluted) of -$0.13 in Q1 2026.
How has Adaptive Biotechnologies's EPS (diluted) changed year-over-year?
Adaptive Biotechnologies's EPS (diluted) increased by 35.0% year-over-year, from -$0.20 to -$0.13.
What is the long-term trend for Adaptive Biotechnologies's EPS (diluted)?
Over 4 years (2021 to 2025), Adaptive Biotechnologies's EPS (diluted) has grown at a -27.9% compound annual growth rate (CAGR), from -$1.48 to -$0.40.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Adaptive Biotechnologies's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude